Early access
Sign in
Taking people in United StatesNo phase

Compares a skin glucose sensor with finger-stick tests in type 1 diabetes

Compares a skin glucose sensor with finger-stick tests in hospital adults with diabetes.

Key facts

Who runs it
Emory University
Where
Atlanta, United StatesSee the site
Trial code
Registry title
A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
Status
Recruiting
People taking part
100 people, planned
Started
12 May 2025
Planned end
Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dexcom G7 rtCGM
  • Capillary Blood glucose Testing (POC)
Record updated
8 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with poorly controlled type 1 diabetes who are in hospital. It compares a Dexcom G7 glucose sensor with finger-prick blood glucose testing.

Age
18 years or older
Sex
All sexes can join
Disease stage
Known type 1 diabetes treated with insulin, admitted with poorly controlled diabetes (blood glucose > 180 mg/dl (10 mmol/L), HbA1c > 7% (53 mmol/mol)), including diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS). Expected hospital stay of more than three days at randomization.
Earlier treatment
Must be treated with insulin. Must not have used a continuous glucose monitor (CGM) before admission.
Biomarker or test result
Blood glucose > 180 mg/dl (10 mmol/L) and HbA1c > 7% (53 mmol/mol) at admission.

Main reasons for not taking part

  • Admitted to the ICU
  • Type 2 diabetes
  • Pregnant or breastfeeding at enrollment
  • Kidney disease with eGFR < 30 ml/min, liver cirrhosis with portal hypertension, or terminal illness
  • Not willing to wear a CGM device

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Known history of T1D treated with insulin therapy (human regular or rapid-acting analogs or ultra-rapid analogs [lispro, aspart, glulisine, fast-acting insulin aspart, insulin lispro]), intermediate-acting (NPH and premixed formulations) or long-acting basal (glargine, detemir, degludec) formulations
  • Admission diagnosis of T1D with poorly controlled diabetes (blood glucose > 180 mg/dl, HbA1c > 7%), including diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS)
  • Expected length of hospital stay > three days at the time of randomization

Who cannot take part

  • Treatment with systemic immunosuppressive agents
  • Subjects with type 2 diabetes
  • Subjects with a history of cognitive impairment, dementia, or mental condition rendering the subject unable to understand the nature and consequences of the study
  • Subjects with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension) and end-stage kidney disease (eGFR< 30 ml/min), or terminal illness
  • Patients admitted to the ICU
  • Subjects using CGM technology before admission
  • Cystic fibrosis
  • Prisoners
  • Patients expected to require MRI procedures during hospitalization
  • Female subjects who are pregnant or breastfeeding at enrollment into the study
  • Subjects not willing to wear a CGM device

Where in United States

  • Grady Memorial HospitalAtlanta, United StatesContact: Guillermo Umpierrez, MDTaking people

About the trial

What the trial wants to find out

This study aims to compare inpatient glycemic control by measuring the percentage of time in the range of 70-180 mg/dl and the frequency of hypoglycemia between Dexcom G7 Continuous Glucose Monitoring (CGM) and Point of Care (POC) Blood Glucose Testing in poorly controlled subjects with Type 1 Diabetes Mellitus.

Read full original descriptionShow less

The main question it aims to answer is:

-Whether there is a difference between POC testing (standard of care) and Real-time CGM in glycemic control and hypoglycemic events during hospitalization:

The 2 groups in the trial

  • Standard of CareExisting treatment, for comparison

    Severe hyperglycemia will be managed by primary care professionals (Hospitalist Service) with intravenous or subcutaneous insulin therapy. Subjects will be invited to participate in the study after the resolution of severe hyperglycemia (BG \< 400 mg/dl). Glucose monitoring by POC testing will be performed before meals and at bedtime. Results will be uploaded to the electronic medical record (EMR) system. The research team, together with the Primary care (PCP) team, will adjust daily insulin orders based on POC readings (standard of care). In addition, subjects will wear a 'blinded' CGM (no results will be visualized by patients, nursing staff, medicine, or research teams) during hospitalization for up to 10 days.

    Treatment: Capillary Blood glucose Testing (POC)

  • Dexcom CGMTreatment being tested

    Severe hyperglycemia will be managed by primary care professionals (Hospitalist Service) intravenously with subcutaneous insulin therapy. Subjects will be invited to participate in the study after the resolution of severe hyperglycemia (BG \< 400 mg/dl). Subjects will wear a real-time Dexcom G7 CGM for up to 10 days. Insulin therapy will be titrated based on daily CGM reports, including mean glucose, glycemic excursions, hypoglycemia, and severe hyperglycemia \> 180 and \>250 mg/dl values. Participants will wear a Dexcom rtCGM for up to 10 days during hospitalization.

    Treatment: Dexcom G7 rtCGM

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized Controlled Trial Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
Plain-language title
Compares a skin glucose sensor with finger-stick tests in type 1 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
8 October 2025